[go: up one dir, main page]

WO2012030309A2 - Formulation d'un inhibiteur des canaux calciques - Google Patents

Formulation d'un inhibiteur des canaux calciques Download PDF

Info

Publication number
WO2012030309A2
WO2012030309A2 PCT/TR2011/000199 TR2011000199W WO2012030309A2 WO 2012030309 A2 WO2012030309 A2 WO 2012030309A2 TR 2011000199 W TR2011000199 W TR 2011000199W WO 2012030309 A2 WO2012030309 A2 WO 2012030309A2
Authority
WO
WIPO (PCT)
Prior art keywords
dry powder
powder formulation
pharmaceutically acceptable
formulation according
calcium channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000199
Other languages
English (en)
Other versions
WO2012030309A3 (fr
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP11767092.7A priority Critical patent/EP2611447A2/fr
Publication of WO2012030309A2 publication Critical patent/WO2012030309A2/fr
Publication of WO2012030309A3 publication Critical patent/WO2012030309A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the present invention relates to a dry powder formulation comprising at least one calcium channel blocker and tiotropium developed in order to be used in respiratory tract diseases such as asthma and COPD.
  • Medicaments used in respiratory tract diseases such as asthma and COPD are generally ⁇ 2 - agonists, glucocorticosteroids, leukotriene agonists, mast cell stabilizers and anticholinergics.
  • Anticholinergics which are the most commonly used medicaments today, are used particularly in asthma and COPD.
  • Some of the examples of anticholinergics used in respiratory tract diseases are tiotropium, ipratropium, glycopyrrolate and atropine.
  • the inventor has surprisingly found that a more efficient treatment is provided with a formulation comprising at least one calcium channel blocker and/or pharmaceutically acceptable derivatives thereof together with tiotropium in dry powder form that is an anticholinergic agent in which the average particle size of the active agent is adjusted in the range of 1 ,5 to 4 ⁇ . Furthermore, the inventor has found that the dry powder formulation comprising an active agent, average particle size of which is in the range of 1,5 to 4 ⁇ , together with an excipient which have two different particle sizes as fine and coarse can be delivered to the lungs more effectively. Adjusting the particle sizes in the range of 1,5 to 4 ⁇ , rate of the active agents which adsorb onto the excipient or excipients having two different average particle sizes is increased.
  • the present invention relates to a dry powder formulation comprising tiotropium that is an anticholinergic, at least one calcium channel blocker and/or its pharmaceutically acceptable derivatives and at least one pharmaceutically acceptable carrier in which the average particle size of the active agent is adjusted in the range of 1,5 to 4 ⁇ and at least one carrier has two different average particle sizes.
  • the present invention provides a medicament used once a day with the dry powder formulation comprising tiotropium, at least one calcium channel blocker and/or its pharmaceutically acceptable derivatives and at least one pharmaceutically acceptable carrier.
  • a treatment with reduced dose frequency can be applied.
  • the present invention provides a treatment in which the progression of the patient can be traced more easily.
  • the present invention provides a dry powder formulation in which the average particle size of its active agent is adjusted in the range of 1,5 to 4 ⁇ . According to the present invention, coarse particles were caught in the upper respiratory tract and could not go further after inhaled. An effective treatment has been provided with the active agents which have an average particle size in the range of 1 ,5 to 4 ⁇ in the dry powder formulations of the present invention.
  • At least one pharmaceutically acceptable calcium channel blocker and/or pharmaceutically acceptable derivatives thereof in the dry powder formulation can be selected from a group comprising amlodipine, azelnidipine, barnidipine, benidipine, clevidipine, felodipin, lercanidipine, nicardipine, nifedipine, nilvadipine, verapamil, gallopamil and diltiazem, and preferably it is nifedipine, nilvadipine, verapamil and diltiazem.
  • At least one pharmaceutically acceptable calcium channel blocker and/or pharmaceutically acceptable derivatives thereof in the dry powder formulation comprises solvates, hydrates, enantiomers or diastereomers, racemates, free base, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of the calcium channel blocker and/or a combination thereof.
  • the amount of at least one pharmaceutically acceptable calcium channel blocker and/or pharmaceutically acceptable derivatives thereof in the dry powder formulation is in the range of 0,01 mg to 100 mg and preferably in the range of 0,1 to 50 mg.
  • tiotropium and/or pharmaceutically acceptable derivatives thereof in the dry powder formulation comprises solvates, hydrates, enantiomers or diastereomers, racemates, free base, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of tiotropium and/or a combination thereof; preferably, it is bromide salt.
  • it could also be in hydrate, anhydrous and hemihydrates
  • the amount of tiotropium and/or pharmaceutically acceptable derivatives thereof is in the range of 1 to 25 ⁇ g and preferably in the range of 5 to 20 ⁇ ⁇ .
  • the dry powder formulation comprises at least one carrier which has two different average particle sizes.
  • the dry powder formulation of the present invention can comprise excipient having two different average particle sizes as fine and coarse.
  • the active agent can reach the lungs more easily during inhalation.
  • Fine particles adsorb onto the active areas on the coarse particles that the formulation comprises.
  • Fine particles also have active areas.
  • coarse particles may get caught in the upper respiratory tract. In this case, the fine particles on the active areas of the coarse particles are released with the active agents and effectively transmitted to the lungs.
  • Average radius of fine excipient particles comprised in the pharmaceutical composition of the present invention is smaller than 10 ⁇ , preferably smaller than 5 ⁇ and more preferably smaller than 3 ⁇ .
  • Average radius of coarse excipient particles is in the range of 10 to 500 ⁇ , preferably in the range of 50 to 300 ⁇ and more preferably in the range of 100 to 200 ⁇ .
  • the present invention provides a dry powder formulation in which the amount of fine excipient particles is 10% or less than 10% of total excipient weight.
  • the excipient comprised in the dry powder formulation can be selected from a group comprising monosaccharides (glucose, etc.), disaccharides (lactose, cellobiose, saccharose, maltose, etc.), oligosaccharides and polysaccharides (dextran, etc.), polyalcohols (sorbitol, mannitol, xyolitol, etc.), salts (sodium chloride, calcium carbonate, etc.), inositol and/or their isomers (myoinositol, etc.) or a combination thereof though it is preferably lactose.
  • monosaccharides glucose, etc.
  • disaccharides lactose, cellobiose, saccharose, maltose, etc.
  • oligosaccharides and polysaccharides oligosaccharides and polysaccharides
  • polyalcohols sorbitol, mannito
  • the amount of excipient in the dry powder formulation comprising active agent and excipient is in the range of 0-50 mg and preferably in the range of 3-20 mg.
  • the present invention provides administration of the medicament comprising tiotropium, at least one calcium channel blocker and/or pharmaceutically acceptable derivatives thereof via dry powder inhalers.
  • the present invention provides administration of the medicament comprising tiotropium, at least one calcium channel blocker and/or pharmaceutically acceptable derivatives thereof via single dose or multiple dose inhalers.
  • the present invention provides a method comprising administration of the medicament composition comprising tiotropium, at least one calcium channel blocker and/or pharmaceutically acceptable derivatives thereof via dry powder inhaler in which the composition is stored in peelable blister packs, reservoir or capsules for treatment of people suffering respiratory diseases.
  • the dry powder formulation comprising more than one dose resides in the reservoir of the device and one dose of the dry powder medicament is inhaled by the patient when the device is activated.
  • the pharmaceutical composition comprising tiotropium, at least one calcium channel blocker and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more active agents and/or pharmaceutically acceptable derivatives thereof selected from a group comprising mast cell stabilizer, anticholinergic, adrenergic agonist, glucocorticosteroid, xanthine, anti leukotriene, PDEIV inhibitor, EGFR inhibitor, anti-allergic, anti-inflammatory, antihistaminic and antimuscarinic substances.
  • the pharmaceutical composition comprising tiotropium, at least one calcium channel blocker and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more substances selected from a group comprising mast cell stabilizers such as chromoglycate and nedocromile; anticholinergics such as ipratropium, glycopyrronium and oxytropium; p 2 -agonists such as carmoterol, formoterol, arformoterol, bambuterol, salmeterol, clenbuterol, salbutamol, fenoterol, terbutaline, carbuterol and pirbuterol; corticosteroids such as beclomethasone, ciclesonide, budesonide, fluticasone and mometasone; xanthines such as doxyphyllin, theobromine and theophylline; antileukotrienes such as montelukast, pranlucast, zafirlukast,
  • composition comprising tiotropium, at least one calcium channel blocker and/or pharmaceutically acceptable derivatives thereof according to the present invention can be used in the treatment of many respiratory diseases, particularly in asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • these respiratory diseases can be, but not limited to, asthma at any stage, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airway hyperactivity, bronchiectasis, chronic obstructive pulmonary including emphysema and chronic bronchitis, respiratory diseases or lung diseases (COPD, COAD or COLD), pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis.
  • This treatment can be prophylactic or symptomatic.
  • the composition of the present invention is especially used for symptomatic treatment of asthma and COPD.
  • composition of the present invention can be explained with, but not limited to, the examples given below.
  • a dry powder formulation suitable to be stored in blister packs for use in a multi-dose inhalation device comprises 9 parts of tiotropium, 400 parts of diltiazem having an average particle diameter in the range of 1,5 to 4 ⁇ ; and 9000 parts of lactose having an average particle diameter below 300 ⁇ and 1000 parts of lactose having an average particle diameter below 10 ⁇ as carrier all of which were micronized in air jet mill.
  • the active agent tiotropium given in this example comprises all pharmaceutically acceptable racemates, enantiomers or diastereomers, solvates, esters, hydrates and/or the free base, polymorphs, amorphous and crystalline forms, and the active agent diltiazem comprises all pharmaceutically acceptable salts, solvates, esters, hydrates and/or enantiomers, polymorphs, amorphous and crystalline forms thereof.
  • the pharmaceutically acceptable carrier given in this example can optionally be added in a higher or a lower amount.
  • a dry powder formulation which is suitable for a gelatine capsule used in capsule inhalator comprises 18 parts of tiotropium, 800 parts of nifedipine having an average particle diameter in the range of 1,5 to 4 ⁇ ; and 10000 parts of lactose having a particle diameter below 300 ⁇ and 900 parts of lactose having an average particle diameter below 10 ⁇ as carrier all of which were micronized in air jet mill.
  • the active agent tiotropium given in this example comprises all pharmaceutically acceptable racemates, enantiomers or diastereomers, solvates, esters, hydrates and/or the free base, polymorphs, amorphous and crystalline forms, and the active agent nifedipine comprises all pharmaceutically acceptable salts, solvates, esters, hydrates and/or enantiomers, polymorphs, amorphous and crystalline forms thereof.
  • the pharmaceutically acceptable carrier given in this example can optionally be added in a higher or a lower amount.
  • the capsule in this example is made of gelatin; it can optionally be made of chitosan, starch and/or derivatives of starch, cellulose and/or cellulose derivatives or synthetic polymers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation de poudre sèche, comprenant au moins un inhibiteur des canaux calciques et le tiotropium, qui a été développée pour être utilisée dans le traitement des maladies des voies respiratoires tel que l'asthme et la BPCO.
PCT/TR2011/000199 2010-09-01 2011-08-24 Formulation d'un inhibiteur des canaux calciques Ceased WO2012030309A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11767092.7A EP2611447A2 (fr) 2010-09-01 2011-08-24 Formulation comprenant le tiotropium et un inhibiteur des canaux calciques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07251 2010-09-01
TR2010/07251A TR201007251A2 (tr) 2010-09-01 2010-09-01 Kalsiyum kanal blokörü formülasyonu.

Publications (2)

Publication Number Publication Date
WO2012030309A2 true WO2012030309A2 (fr) 2012-03-08
WO2012030309A3 WO2012030309A3 (fr) 2012-08-09

Family

ID=44764205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000199 Ceased WO2012030309A2 (fr) 2010-09-01 2011-08-24 Formulation d'un inhibiteur des canaux calciques

Country Status (3)

Country Link
EP (1) EP2611447A2 (fr)
TR (1) TR201007251A2 (fr)
WO (1) WO2012030309A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2482658A4 (fr) * 2009-09-30 2013-12-25 Microdose Therapeutx Inc Procédés et compositions pour le traitement du phénomène de raynaud
JP2015003836A (ja) * 2013-06-19 2015-01-08 日本碍子株式会社 単結晶体の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092267A2 (fr) 2000-05-30 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. Medicaments a base de dihydropyridine, compositions et procedes associes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU601695B2 (en) * 1985-07-02 1990-09-20 Key Pharmaceuticals, Inc. Method and composition for the treatment of chronic obstructive pulmonary disease
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
JP3870159B2 (ja) * 2000-10-12 2007-01-17 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト チオトロピウムを含む新規吸入性粉剤
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
WO2008152398A2 (fr) * 2007-06-14 2008-12-18 Cipla Limited Formulations pour inhalation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092267A2 (fr) 2000-05-30 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. Medicaments a base de dihydropyridine, compositions et procedes associes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2482658A4 (fr) * 2009-09-30 2013-12-25 Microdose Therapeutx Inc Procédés et compositions pour le traitement du phénomène de raynaud
JP2015003836A (ja) * 2013-06-19 2015-01-08 日本碍子株式会社 単結晶体の製造方法

Also Published As

Publication number Publication date
EP2611447A2 (fr) 2013-07-10
WO2012030309A3 (fr) 2012-08-09
TR201007251A2 (tr) 2012-03-21

Similar Documents

Publication Publication Date Title
WO2011136754A1 (fr) Médicament mis au point pour le traitement de maladies respiratoires
US20100329996A1 (en) Novel Combination of Therapeutic Agents
EP2575786B1 (fr) Procédé pour formulations pulvérulentes sèches
IL143986A (en) Combinations of formotrol and tiotropium salt
WO2003074025A2 (fr) Formulations hfa de beta 2-agonistes a action prolongee de derives de 2(1h)-qiunolinone
AU3284300A (en) Combinations of formoterol and mometasone furoate for asthma
JP2004500429A (ja) チオトロピウム及びロフレポニドを含む医薬用の組み合わせ
EP2209769A1 (fr) Nouveaux sels cristallins de montélukast
JP2020023537A (ja) Ｃｏｐｄの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ
WO2011136753A1 (fr) Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
WO2012030308A2 (fr) Formulation comprenant la cellobiose
WO2012030309A2 (fr) Formulation d'un inhibiteur des canaux calciques
EP2480203B1 (fr) Formulation de poudre sèche de tiotropium contenue dans une bande alvéolée thermoformée
WO2013009271A1 (fr) Nouvelle formulation améliorée de poudre sèche
WO2012166070A1 (fr) Formulation de poudre sèche ayant des caractéristiques d'écoulement améliorées
WO2013109220A1 (fr) Formulations en poudre sèche comprenant du tiotropium, du formotérol et du budésonide
WO2011136752A1 (fr) Composition pharmaceutique combinée comprenant du carmotérol et du ciclésonide pour le traitement de maladies respiratoires
EP2515845B1 (fr) Formulation de poudre sèche comprenant du tiotropium, du formoterol et un derive d'acide cromoglicine
WO2011049539A1 (fr) Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil
EP2528597A1 (fr) Formulation de poudre sèche comprenant des compositions pharmaceutiques combinées de bromure de tiotropium, de fumarate de formotérol et de furoate de mométasone
WO2011078817A1 (fr) Poudre séche combinant tiotropium, mométasone et un dérivé d'acide cromoglicique
TR2023016009A1 (tr) İnhalasyon yoluyla kullanima uygun bi̇r muskari̇ni̇k antagoni̇st etken madde i̇çeren farmasöti̇k bi̇leşi̇mler
TR2023012621A1 (tr) İnhale edi̇lebi̇li̇r formda i̇ti̇ci̇ gaz i̇çermeyen sivi bi̇leşi̇mler
TR2023016006A1 (tr) İnhalasyon yoluyla kullanima uygun bi̇r muskari̇ni̇k antagoni̇st etken madde i̇çeren aerosol bi̇leşi̇mler
TR2023014905A1 (tr) Steroi̇d i̇çeren aerosol bi̇leşi̇mler

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11767092

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011767092

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE